Methylene blue in place of acridine orange as a photosensitizer in photodynamic therapy of osteosarcoma (2008)

Peer-Reviewed Study · Matsubara T; Kusuzaki K; Matsumine A; Satonaka H; Shintani K; Nakamura T; Uchida A · 2008

Matsubara T et al., 2008: Animal and cell study testing methylene blue as a replacement for acridine orange in photodynamic therapy of osteosarcoma. Methylene blue killed cells in culture under light but did not accumulate in mouse osteosarcoma tissue and did not inhibit tumour growth in vivo, and it showed no radiodynamic effect.

In vivo studies showed that MB did not specifically accumulate in mouse osteosarcoma tissue and that it did not inhibit tumor growth.

Matsubara T et al., 2008: Animal and cell study testing methylene blue as a replacement for acridine orange in photodynamic therapy of osteosarcoma. Methylene blue killed cells in culture under light but did not accumulate in mouse osteosarcoma tissue and did not inhibit tumour growth in vivo, and it showed no radiodynamic effect. Study type: in vitro mouse osteosarcoma (LM8) cells plus in vivo mouse tumour model. N: animals per full text. Country: Japan (Mie University). Dose/route: methylene blue per full text; in vivo intravenous. Comparator: acridine orange protocol and untreated controls. Funder/conflicts: not stated in record. Bearing is toward C8 (the existence of contrary evidence), not toward methylene blue's efficacy: this is a clean negative in vivo result, and it is the study the Frontiers 2023 review (MTM-01) cites for 'MB did not inhibit osteosarcoma growth in mice'. Study type: animal.